+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06440993

Durvalumab Combined with Chemotherapy and Intraductal Radiofrequency Ablation in Treating Patients with Unresectable Extra- and Intrahepatic Cholangiocarcinoma A Phase II, Single-Arm, Open-Label Trial

Led by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Updated on 2026-10-23

42

Participants Needed

12

Research Sites

65 weeks

Total Duration

AI-Summary

What This Trial Is About

This clinical trial is a phase II, single-arm, open-label study investigating the combination of durvalumab with intraductal radiofrequency ablation ID-RFA followed by chemotherapy in patients with unresectable extra- and intrahepatic cholangiocarcinoma. The trial focuses on patients who have bile duct stenting and palliative systemic therapy needs, aiming to assess whether this combination increases anti-tumor activity. Participants will receive systemic treatment consisting of gemcitabine and cisplatin given intravenously on days 1 and 8 of each 3-week cycle for 8 cycles, combined with durvalumab given intravenously on day 1 and continued as maintenance therapy. The treatment includes two sessions of endoscopic intraductal radiofrequency ablation. This combination therapy is administered under close medical supervision throughout the study. During the trial, participants will undergo scheduled visits including treatment administration and follow-up assessments. Researchers will monitor overall survival at 12 months as the primary outcome and secondary outcomes such as progression-free survival, adverse events, time to cholangitis, and quality of life using standardized questionnaires. Safety and laboratory parameters will be regularly evaluated, with the study following participants up to three years. Total study participation may last until study completion in 2028.

CONDITIONS

Brief Title

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma

Research Team

C

Christoph Roderburg, Prof. Dr.

J

Johanna Riedel, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here